Literature DB >> 29316226

A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options.

Nicklas Järvelä Johansen1,2, Mikkel Bring Christensen1.   

Abstract

A large overdose of insulin is a serious health matter. Information concerning administration and duration of intravenous (IV) glucose, other treatment options or complications besides hypoglycaemia following large insulin overdoses is not readily apparent from the literature. A systematic search, compilation and review of case reports on insulin overdoses, published 1986-2017, was performed in PubMed, EMBASE, Cochrane and PROSPERO databases. Of 1523 published articles, 45 cases of insulin overdoses were included with a total median insulin dose of 900 international units (IU) (range 26-4800 IU). Hospitalization occurred in 44 cases with a median hospitalization duration of 94 hr (range 12-721 hr), and one-third (n = 15) admitted to the intensive care unit. First-line treatment was IV glucose treatment in 95% of cases. Treatment options besides IV glucose that were reported beneficial included glucagon IV or intramuscular (IM), octreotide IV or IM, surgical excision, hydrocortisone IV and oral intake of complex carbohydrates. Prevalent complications were intermittent cerebral impairment (73%), hypokalaemia (49%), other electrolyte disturbances (42%), and hepatic disturbances (7%) and cardiac toxicity (e.g. cardiac arrhythmia) (9%). Long-term consequences were one case of lasting hypoglycaemic encephalopathy and one death. In conclusion, following large insulin overdoses, in-hospital admission and treatment with IV glucose may be needed for up to a week. Monitoring of electrolytes and hepatic and cardiac functions seems important. Several experimental treatment options may be considered in addition to glucose administration. With appropriate pre- and in-hospital treatment, cases with severe hypoglycaemia and neurologic complications may have a favourable outcome.
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29316226     DOI: 10.1111/bcpt.12957

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  6 in total

1.  Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin.

Authors:  Jung Seok Lee; Patrick Han; Rabib Chaudhury; Shihan Khan; Sean Bickerton; Michael D McHugh; Hyun Bong Park; Alyssa L Siefert; Gerald Rea; José M Carballido; David A Horwitz; Jason Criscione; Karlo Perica; Robert Samstein; Ragy Ragheb; Dongin Kim; Tarek M Fahmy
Journal:  Nat Biomed Eng       Date:  2021-10-06       Impact factor: 25.671

2.  Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system.

Authors:  Harmony Thompson; Helen Lunt; Cate Fleckney; Steven Soule
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-06-01

3.  Insulin overdose complicated by treatment-induced acute hepatic steatosis in a nondiabetic patient.

Authors:  Noriyuki Okamoto; Shinsuke Onishi; Toshiyuki Onodera; Toshihiro Tawara; Hiroyuki Okamoto; Takafumi Shimizu; Akiko Oshiro; Yuka Morishita; Satoshi Nara
Journal:  Acute Med Surg       Date:  2022-07-22

4.  Biodistribution of Insulin Following Massive Insulin Subcutaneous Injection.

Authors:  Tomoya Ikeda; Naoto Tani; Tatsuya Hirokawa; Kei Ikeda; Fumiya Morioka; Alissa Shida; Yayoi Aoki; Takaki Ishikawa
Journal:  Intern Med       Date:  2022-03-12       Impact factor: 1.282

5.  Inadvertent iatrogenic insulin detemir 1000 units overdose in a hospitalised patient.

Authors:  Sudan Thapa; Germin Fahim; Sudha Ganne
Journal:  BMJ Case Rep       Date:  2019-12-29

Review 6.  The Other Face of Insulin-Overdose and Its Effects.

Authors:  Szymon Rzepczyk; Klaudia Dolińska-Kaczmarek; Aleksandra Uruska; Czesław Żaba
Journal:  Toxics       Date:  2022-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.